查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1781185

动物用神经退化性疾病诊断的按全球市场，各产品类型，诊断试验，动物的类别，各适应症，各最终用途，各地区，机会，预测，2018年～2032年

Global Veterinary Neurodegenerative Disease Diagnostics Market Assessment, By Product Type, By Diagnostic Tests, By Animal Type, By Indication, By End-Use, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 232 Pages | 商品交期: 3-5个工作天内

价格

全球动物神经退化性疾病诊断市场预计将从2024年的4亿美元成长到2032年的7.1亿美元，预测期间（2025-2032年）的复合年增长率为7.47%。动物神经退化性疾病诊断市场持续稳定成长，部分原因是人们对动物神经系统疾病的认识不断提高，以及对早期准确诊断的需求不断增长。许多诊断技术创新，例如基于人工智慧的成像、便携式MRI成像和分子生物标记评估，都与兽医学息息相关。这些进步正在彻底改变兽医检测、监测和评估伴侣动物复杂疾病（包括认知功能障碍）的方式。宠物饲养的日益普及以及人们与伴侣动物之间情感纽带的加深，也推动了专科护理支出的增加。

此外，宠物保险和政府资助的牲畜保险计划的扩大，正在降低成本相关的障碍，并使人们能够更广泛地获得先进的诊断服务。持续的技术创新，加上对兽医研究的投入增加和临床基础设施的改善，正在塑造这个不断发展的市场的未来发展中发挥关键作用。

例如，2024年10月，WOORIEN有限公司推出了MyVet CT Plus。 MyVet CT Plus是一款螺旋线性兽用CT扫描仪，其扫描和重建时间显着缩短，成像时间最多可缩短80%，并且具有灵活的视野，适用于从小型爬行动物到大型犬等各种动物，使各种兽医诊所都能更容易地获得先进的影像诊断服务。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 全球动物用神经退化性疾病诊断市场展望，2018年～2032年

  • 市场规模分析与预测
    • 各金额
  • 市场占有率分析与预测
    • 各产品类型
      • 消耗品，试剂，套件
      • 设备和器具
    • 诊断试验
      • 影像诊断
      • 生物标记诊断检验
      • 其他
    • 动物的类别
      • 家畜
      • 伴同性
    • 各适应症
      • 认识功能障碍
      • 小脑萎缩症
      • 海绵状脑病变
      • 其他
    • 各最终用途
      • 动物医院和诊疗所
      • 兽医诊断研究所
      • 其他
    • 各地区
      • 北美
      • 欧洲
      • 亚太地区
      • 南美
      • 中东·非洲
    • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
  • 2024年市场地图分析
    • 各产品类型
    • 诊断试验
    • 动物的类别
    • 各适应症
    • 各最终用途
    • 各地区

第6章 北美的动物用神经退化性疾病诊断市场展望，2018年～2032年

  • 市场规模分析与预测
    • 各金额
  • 市场占有率分析与预测
    • 各产品类型
      • 消耗品，试剂，套件
      • 设备和器具
    • 诊断试验
      • 影像诊断
      • 生物标记诊断检验
      • 其他
    • 动物的类别
      • 家畜
      • 伴同性
    • 各适应症
      • 认识功能障碍
      • 小脑萎缩症
      • 海绵状脑病变
      • 其他
    • 各最终用途
      • 动物医院和诊疗所
      • 兽医诊断研究所
      • 其他
    • 各国占有率
      • 美国
      • 加拿大
      • 墨西哥
  • 各国市场评估
    • 美国的动物用神经退化性疾病诊断市场展望，2018年～2032年预测
      • 市场规模分析与预测
      • 市场占有率分析与预测
    • 加拿大
    • 墨西哥

所有部门市市场均涵盖所有地区和国家。

第7章 欧洲的动物用神经退化性疾病诊断市场展望，2018年～2032年

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第8章 亚太地区的动物用神经退化性疾病诊断市场展望，2018年～2032年

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第9章 南美的动物用神经退化性疾病诊断市场展望，2018年～2032年

  • 巴西
  • 阿根廷

第10章 中东·非洲的动物用神经退化性疾病诊断市场展望，2018年～2032年

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势与发展

第17章 法规结构和革新

第18章 案例研究

第19章 竞争情形

  • 前五名市场领导公司的竞争矩阵
  • 前五名企业的SWOT分析
  • 前10名市场主要企业的形势
    • Zoetis Inc.
      • 公司概要
      • 主要经营团队
      • 产品和服务
      • 财务状况(报告那样)
      • 主要市场的着重和地理存在感
      • 最近的趋势/合作/伙伴关係/合併和收购
    • Virbac SA
    • Life Diagnostics, Inc.
    • ACUVET Biotech
    • Merck Animal Health(Merck &Co., Inc.)
    • IDEXX Laboratories, Inc.
    • MI:RNA Diagnostics Ltd.
    • Mercodia AB
    • Antech Diagnostics, Inc.
    • Avacta Animal Health Limited

以上公司非基于市场份额排序，并且可能会根据研究过程中可用的信息而变化。

第20章 策略性建议

第21章 关于调查公司·免责声明

Product Code: MX13843

Global veterinary neurodegenerative disease diagnostics market is projected to witness a CAGR of 7.47% during the forecast period 2025-2032, growing from USD 0.40 billion in 2024 to USD 0.71 billion in 2032. The veterinary neurodegenerative disease diagnostics market continues to grow in a consistent manner, partially due to the increase in awareness of neurological disorders in animals and the need for early and accurate diagnostics. Many innovations in diagnostics have great significance and relevance to veterinary medicine, such as artificial intelligence-assisted imaging, portable imaging in the form of MRI, and molecular biomarker assessments. This is significantly changing the ways in which veterinarians detect, monitor and assess complex diseases in companion animals including cognitive dysfunction. Increased levels of pet ownership and the emotional bond that people have with their companion animals also influence the increased spending for specialty care.

Additionally, the expansion of pet insurance and government-supported livestock insurance schemes is reducing cost-related barriers and enabling wider access to advanced diagnostics. Continuous technological innovation, combined with growing investment in veterinary research and improved clinical infrastructure, plays a vital role in shaping the future of this evolving market.

For instance, in October 2024, WOORIEN Co., Ltd. launched the MyVet CT Plus, a spiral-linear veterinary CT scanner featuring significantly faster scan and reconstruction times-reducing acquisition by up to 80%-and a flexible field-of-view suitable for animals from small reptiles to large dogs, making advanced imaging more accessible to diverse veterinary practices

Advancements in Diagnostic Technologies Driving Precision in Veterinary Neurodegenerative Disease Diagnostics

Veterinary neurodegenerative diagnostics is rapidly evolving with the integration of advanced technologies. Newer technologies, such as AI based imaging, high field MRI, and biomarker-based testing, will lead to earlier and more precise identification of complex neurological problems. In addition to offering more precise identification of disease, these technologies also provide improved characterization of the disease, assist with planning treatment, and provide ongoing assessment of treatment efficacy. The transition to digital systems and point-of-care diagnostics will enhance accessibility to diagnostics in all aspects of veterinary practice ranging from no/vet to urban/rural contexts. Advanced imaging, specifically MRI has evolved significantly in its ability to assess and identify subtle brain and spinal abnormalities. The ability progressively to document and assess a patient's disease over time will provide the veterinary clinician with substantial insights into disease progression and prognosis. Advances in technology are changing the landscape of veterinary neurology.

For instance, in June 2025, Siemens Healthineers gained FDA clearance for the Magnetom Flow.Ace 1.5 T MRI scanner, developed for both human and veterinary applications. Featuring AI-powered image reconstruction and an energy-efficient CoolDry helium system, the scanner enhances soft-tissue visualization, shortens scan durations, and adapts to diverse animal anatomies, marking a significant advancement in veterinary neurodiagnostic imaging.

Growing Pet Insurance Coverage Fuels Market Expansion

The increasing availability and uptake of pet insurance is one of the most important factors contributing to the growth of the veterinary neurodegenerative disease diagnostics market. Because diagnostic tools like MRIs, CTs, and biomarker tests can be expensive, insurance coverage opens up options for clients without the affordability barrier. Many policies now cover advanced diagnostic services; thus, veterinarians can now recommend full neurological evaluations without excess financial concern. This not only helps pet owners get an early and accurate diagnostic outcome when assessing if neurodegenerative disease is present, insurance had also opened the gate for veterinarians to adopt advanced technology by providing the immediate financial support necessary. The financial resources from insurance have quickened the pace of precision diagnostics and is helping to shape the future of the market.

For instance, in March 2025, according to Press Information Bureau, Government of India Under the National Livestock Mission (NLM), 21.01 lakh livestock animals were insured in the current financial year, supporting access to veterinary diagnostics, including neurodegenerative disease detection, by reducing financial barriers for farmers through demand-driven insurance coverage.

MRI Imaging Leads in Veterinary Neurodegenerative Diagnostics Market

MRI has emerged as the leading diagnostic tool in the veterinary neurodegenerative diagnostics market. As a non-invasive imaging technique, MRI excels at producing high-quality images of the brain and spinal cord, allowing for the identification of various conditions, regardless of their etiology, including cognitive dysfunction, cerebellar abiotrophy and other neurodegenerative diseases. MRI is set apart from other imaging techniques by its exceptional soft tissue contrast and absence of radiation exposure, making it a safer proposition. As a result, veterinary clinics and specialty hospitals are installing MRI systems into their practices to allow for rapid and accurate assessment of animals. The increase in demand for advanced neurological diagnostic testing provided to companion animals (dogs and cats) has further justified the use of MRI in a veterinary setting. With improved technology and availability of high-field MRI systems, this segment continues to gain momentum within the veterinary imaging market.

For instance, in October 2024, InkSpace Imaging LLC introduced the Nuzzle veterinary array, a new and innovative MRI coil that is approved for animal use. This will allow for much clearer, high-resolution images to drive detection and diagnosis of neurological diseases and disorders in the field of veterinary medicine.

North America Leads the Veterinary Neurodegenerative Diagnostics Market

North America holds a dominant position in the veterinary neurodegenerative diagnostics market. The main reason behind this is its well-developed veterinary healthcare system and high awareness among pet owners regarding neurological conditions in animals. The North America region is generally characterized by strong research and development funding, robust regulatory frameworks, strong veterinary healthcare systems, partnerships between academia, diagnostic developers, and commercialization support. The North America region has a large population of companion and performance animals along with an abundance of skilled veterinary professionals. The overall focus of North America is on the early and accurate detection of disease, and it has so far supported and sustained all the necessary elements to lead the way in veterinary neurodegenerative diagnostics.

For instance, in March 2025, NVIDIA Corporation and GE HealthCare Technologies Inc. announced a partnership to develop autonomous diagnostic imaging systems using physical AI. This collaboration leverages simulation and robotics to improve imaging accuracy and efficiency in clinical settings.

Impact of U.S. Tariffs on Veterinary Neurodegenerative Disease Diagnostics Market

Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.

Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries. Companies may select to work with domestic suppliers or alternate suppliers, which affect time.

Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.

Higher prices and lower availability may inhibit any growth of the market in the interim time.

Key Players Landscape and Outlook

The key players operating the market are focusing on innovation, strategic partnerships, and continuing advancements in diagnostics. Their priority is to the develop improved tools for the early detection of neurodegenerative diseases in the veterinary setting. Most of the companies are investing in artificial intelligence and digital image assessment tools to improve accuracy and efficiency of diagnostics. Others are emphasizing point-of-care testing to provide rapid diagnostics in a clinical environment. Many are emphasizing the expansion of laboratory networks as well as the integration of diagnostics with the treatment protocols. Other companies are partnering with research institutions to assess new biomarkers and neuroimaging. The greater usage of cloud-based diagnostic resources is expediting diagnostic workflows and promoting processes that allow data transfer sharing. Thus, the focus is on technological advancement, accessibility, and achieving better diagnostic decisions about difficult neurodegenerative issues in animals.

For instance, in January 2025, Zoetis Inc. launched an enhanced Vetscan Imagyst with 6-in-1 AI-powered diagnostics, including blood, fecal, dermatology, and urine analysis, advancing speed and accuracy in veterinary neuro diagnostics.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product Type
      • 5.2.1.1. Consumables, Reagents, and Kits
      • 5.2.1.2. Equipment and Instruments
    • 5.2.2. By Diagnostic Tests
      • 5.2.2.1. Imaging
        • 5.2.2.1.1. MRI (Magnetic Resonance Imaging)
        • 5.2.2.1.2. CT (Computed Tomography)
        • 5.2.2.1.3. Others
      • 5.2.2.2. Biomarker Diagnostic Tests
        • 5.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
        • 5.2.2.2.2. Blood-based Biomarkers
        • 5.2.2.2.3. Others
      • 5.2.2.3. Others
    • 5.2.3. By Animal Type
      • 5.2.3.1. Livestock
        • 5.2.3.1.1. Sheep
        • 5.2.3.1.2. Cattle
        • 5.2.3.1.3. Others
      • 5.2.3.2. Companion
        • 5.2.3.2.1. Canine
        • 5.2.3.2.2. Feline
        • 5.2.3.2.3. Equine
        • 5.2.3.2.4. Others
    • 5.2.4. By Indication
      • 5.2.4.1. Cognitive Dysfunction
      • 5.2.4.2. Cerebellar Abiotrophy
      • 5.2.4.3. Spongiform Encephalopathies
      • 5.2.4.4. Others
    • 5.2.5. By End-Use
      • 5.2.5.1. Veterinary Hospitals and Clinics
      • 5.2.5.2. Veterinary Diagnostic Laboratories
      • 5.2.5.3. Others
    • 5.2.6. By Region
      • 5.2.6.1. North America
      • 5.2.6.2. Europe
      • 5.2.6.3. Asia-Pacific
      • 5.2.6.4. South America
      • 5.2.6.5. Middle East and Africa
    • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Product Type
    • 5.3.2. By Diagnostic Tests
    • 5.3.3. By Animal Type
    • 5.3.4. By Indication
    • 5.3.5. By End-Use
    • 5.3.6. By Region

6. North America Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Product Type
      • 6.2.1.1. Consumables, Reagents, and Kits
      • 6.2.1.2. Equipment and Instruments
    • 6.2.2. By Diagnostic Tests
      • 6.2.2.1. Imaging
        • 6.2.2.1.1. MRI (Magnetic Resonance Imaging)
        • 6.2.2.1.2. CT (Computed Tomography)
        • 6.2.2.1.3. Others
      • 6.2.2.2. Biomarker Diagnostic Tests
        • 6.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
        • 6.2.2.2.2. Blood-based Biomarkers
        • 6.2.2.2.3. Others
      • 6.2.2.3. Others
    • 6.2.3. By Animal Type
      • 6.2.3.1. Livestock
        • 6.2.3.1.1. Sheep
        • 6.2.3.1.2. Cattle
        • 6.2.3.1.3. Others
      • 6.2.3.2. Companion
        • 6.2.3.2.1. Canine
        • 6.2.3.2.2. Feline
        • 6.2.3.2.3. Equine
        • 6.2.3.2.4. Others
    • 6.2.4. By Indication
      • 6.2.4.1. Cognitive Dysfunction
      • 6.2.4.2. Cerebellar Abiotrophy
      • 6.2.4.3. Spongiform Encephalopathies
      • 6.2.4.4. Others
    • 6.2.5. By End-Use
      • 6.2.5.1. Veterinary Hospitals and Clinics
      • 6.2.5.2. Veterinary Diagnostic Laboratories
      • 6.2.5.3. Others
    • 6.2.6. By Country Share
      • 6.2.6.1. United States
      • 6.2.6.2. Canada
      • 6.2.6.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Product Type
          • 6.3.1.2.1.1. Consumables, Reagents, and Kits
          • 6.3.1.2.1.2. Equipment and Instruments
        • 6.3.1.2.2. By Diagnostic Tests
          • 6.3.1.2.2.1. Imaging
          • 6.3.1.2.2.1.1. MRI (Magnetic Resonance Imaging)
          • 6.3.1.2.2.1.2. CT (Computed Tomography)
          • 6.3.1.2.2.1.3. Others
          • 6.3.1.2.2.2. Biomarker Diagnostic Tests
          • 6.3.1.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
          • 6.3.1.2.2.2.2. Blood-based Biomarkers
          • 6.3.1.2.2.2.3. Others
          • 6.3.1.2.2.3. Others
        • 6.3.1.2.3. By Animal Type
          • 6.3.1.2.3.1. Livestock
          • 6.3.1.2.3.1.1. Sheep
          • 6.3.1.2.3.1.2. Cattle
          • 6.3.1.2.3.1.3. Others
          • 6.3.1.2.3.2. Companion
          • 6.3.1.2.3.2.1. Canine
          • 6.3.1.2.3.2.2. Feline
          • 6.3.1.2.3.2.3. Equine
          • 6.3.1.2.3.2.4. Others
        • 6.3.1.2.4. By Indication
          • 6.3.1.2.4.1. Cognitive Dysfunction
          • 6.3.1.2.4.2. Cerebellar Abiotrophy
          • 6.3.1.2.4.3. Spongiform Encephalopathies
          • 6.3.1.2.4.4. Others
        • 6.3.1.2.5. By End-Use
          • 6.3.1.2.5.1. Veterinary Hospitals and Clinics
          • 6.3.1.2.5.2. Veterinary Diagnostic Laboratories
          • 6.3.1.2.5.3. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

18. Case Studies

19. Competitive Landscape

  • 19.1. Competition Matrix of Top 5 Market Leaders
  • 19.2. SWOT Analysis for Top 5 Players
  • 19.3. Key Players Landscape for Top 10 Market Players
    • 19.3.1. Zoetis Inc.
      • 19.3.1.1. Company Details
      • 19.3.1.2. Key Management Personnel
      • 19.3.1.3. Products and Services
      • 19.3.1.4. Financials (As Reported)
      • 19.3.1.5. Key Market Focus and Geographical Presence
      • 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 19.3.2. Virbac SA
    • 19.3.3. Life Diagnostics, Inc.
    • 19.3.4. ACUVET Biotech
    • 19.3.5. Merck Animal Health (Merck & Co., Inc.)
    • 19.3.6. IDEXX Laboratories, Inc.
    • 19.3.7. MI:RNA Diagnostics Ltd.
    • 19.3.8. Mercodia AB
    • 19.3.9. Antech Diagnostics, Inc.
    • 19.3.10. Avacta Animal Health Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

20. Strategic Recommendations

21. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 3. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 4. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 5. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 6. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 7. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Region, 2018-2032F
  • Figure 8. North America Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 9. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 10. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 11. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 12. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 13. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 14. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
  • Figure 15. United States Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 17. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 18. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 19. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 20. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 21. Canada Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 22. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 23. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 24. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 25. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 26. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 27. Mexico Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 28. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 29. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 30. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 31. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 32. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 33. Europe Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 34. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 35. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 36. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 37. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 38. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 39. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
  • Figure 40. Germany Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 42. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 43. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 44. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 45. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 46. France Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 47. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 48. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 49. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 50. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 51. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 52. Italy Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 54. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 55. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 56. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 57. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 58. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 59. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 60. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 61. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 62. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 63. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 64. Russia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 66. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 67. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 68. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 69. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 70. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 71. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 72. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 73. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 74. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 75. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 76. Spain Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 77. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 78. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 79. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 80. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 81. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 82. Turkey Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 84. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 85. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 86. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 87. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 88. Poland Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 89. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 90. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 91. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 92. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 93. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 94. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 96. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 97. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 98. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 99. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 100. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
  • Figure 101. India Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 103. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 104. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 105. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 106. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 107. China Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 108. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 109. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 110. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 111. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 112. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 113. Japan Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 114. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 115. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 116. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 117. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 118. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 119. Australia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 121. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 122. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 123. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 124. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 125. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 126. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 127. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 128. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 129. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 130. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 131. South Korea Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 133. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 134. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 135. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 136. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 137. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 138. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 139. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 140. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 141. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 142. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 143. Philippines Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 144. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 145. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 146. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 147. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 148. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 149. South America Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 150. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 151. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 152. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 153. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 154. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 155. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
  • Figure 156. Brazil Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 157. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 158. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 159. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 160. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 161. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 162. Argentina Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 163. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 164. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 165. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 166. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 167. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 168. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 169. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 170. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 171. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 172. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 173. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 174. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
  • Figure 175. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 176. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 177. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 178. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 179. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 180. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 181. UAE Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 182. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 183. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 184. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 185. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 186. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 187. South Africa Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 188. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
  • Figure 189. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
  • Figure 190. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
  • Figure 191. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
  • Figure 192. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
  • Figure 193. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 194. By Diagnostic Tests Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 195. By Animal Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 196. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 197. By End-Use Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024